This review discusses the features of oligoarticular, polyarticular, systemic, and psoriatic JIA and enthesitis-related ...

Many people with psoriatic arthritis will experience symptoms in their feet. This can lead to swollen toes, pitted nails, ...

Dactylitis is one of the hallmark symptoms of psoriatic arthritis (PsA). It has earned the nickname “sausage digits” because of the sausage-like look. Dactylitis is more than a symptom. It can ...

Juvenile Psoriatic Arthritis Can Be Stratified Based on Age at Onset —New findings suggest that unification of pediatric and adult psoriatic arthritis criteria may improve diagnosis and ...

Psoriatic arthritis (PsA) can affect different parts of your feet. ... Although dactylitis is a common feature of PsA, swollen feet can be a symptom of PsA before specific joints are affected.

Patients who achieved at least 30% improvement in juvenile idiopathic arthritis American College of Rheumatology (JIA ACR 30) response then moved on to treatment period 2, where they were randomly ...

Secukinumab yielded a significantly longer time to flare than placebo in pediatric patients with enthesitis-related arthritis and juvenile psoriatic arthritis, according to findings presented at ...

Patients with psoriatic arthritis who receive tofacitinib demonstrate “sustained improvements” in dactylitis compared with those who did not receive tofacitinib, according to data published in ...

Psoriatic arthritis (PsA) is a form of inflammatory arthritis. It affects about 1.5 million people in the U.S., or 30% of people who have psoriasis. Psoriasis is a skin disease that causes a red ...

Another one of the common early warning signs of psoriatic arthritis? Dactylitis, or what Dr. Cohen calls “sausage digits”. This causes the joints in your fingers or toes to swell and turn ...

Juvenile psoriatic arthritis (JPA) is a chronic inflammatory condition affecting children under 16, characterized by joint pain, swelling, and a red, scaly rash. Around 0.5 per cent to 2.5 per ...

The approval was based on data from the 2-year phase 3 JUNIPERA study that evaluated secukinumab in pediatric patients aged 2 to 17 years with a confirmed diagnosis of ERA or JPsA.